HealthTech180
  • Home
  • Activities
  • Our Team
  • Contact Us
Select Page

Positive Phase III Results for Narcolepsy Drug with Low Cardiovascular Risk

by admin | Oct 8, 2019 | Clinical Trials

The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease.  In a 200-patient phase III trial that finished in July, Jazz...
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.

Categories

Follow Us

Tags

AI Alzheimer antibodies Azitra Bioeq Biosimilar Cancer cardiovascular cell therapy CE Mark clinical trial Diagnostics Digital Health Distribution Drug Discovery Enterome EpiVax' FDA FDA approval funding fundraising HIV Immunogenicity Immunotherapies Licensing M&A medical device microbiome Neuro next-gen sequencing PathAI pathology Pepticom pharma RNA robots Shape Therapeutics skin software SurgiMab Therapeutics therapies USA VIrology Virus

Home
Activities
Our Team
Contact Us

 contact@healthtech180.com

Privacy Policy

© 2022 HealthTech180 Advisory S.L.